Biosimilars allow a greater number of patients to access high-quality treatments with proven safety and efficacy profiles, our company is committed to the development and production of innovative treatments based on our experience to reach more patients with serious diseases, the biosimilars will help maintain the commitment to connect patients with essential medicines.
The production process of a biosimilar medicine is as complex as that of the original medicine, for which scientists design a cell line and an independent production process, so that the same conditions do not occur in the production process of a medicine.
A biosimilar meets the same quality standard as the original drug and its production process follows the same regulation and control system.
In total, each biosimilar is subject to many quality controls to ensure equivalence with the original drug, its production is long and expensive, unlike the generic, which only has to prove its equivalence with the reference product, the biosimilar must undergo to full clinical development to demonstrate the same efficacy, safety and quality as the drug in question.
We are well positioned to leverage our biotech industry expertise to create high-quality biosimilars and reliably deliver them to patients around the world.
We are committed to high quality and necessary biosimilars for cancer and highly complex diseases.
Our products will expand access to biopharmaceuticals, allowing more patients to benefit from new scientific advances.